Main Directory
Articles 2591
CME 2
eCommerce 0
Medical Web Sites Directory 93
Podcasts 94
Web Design and Hosting 2




Pegylated Arginine Deiminase Has Potential for Unresectable Hepatoma
Link ID 23954
Title Pegylated Arginine Deiminase Has Potential for Unresectable Hepatoma
Url http://www.medscape.com/viewarticle/719582?src=rss
Description Pegylated arginine deiminase might prolong survival in patients with unresectable hepatocellular carcinoma, phase II trial data suggest. Reuters Health Information
Category Articles > Pharmacists
Keywords
Date Apr 2, 2010
Contact Name
Email
Write a Review   Add to My Favorite   Refer it to Friend   Report Broken Link  

Average Visitor Rating: 0.00 (out of 5)
Number of ratings: 0 Votes
Visitor Rating

 Other links at Articles > Pharmacists
1. Unknown Factors May Protect Patients From Ravages of Diabetes
  Glycemic control did not seem to be a factor in determining complication risks from type 1 diabetes of long duration. Medscape Medical News
Category:   Articles > Pharmacists


2. Anti-TNF Agents and Cancer Risk: What to Tell PatientsAnti-TNF Agents and Cancer Risk: What to Tell
  Patients are worried...what can you tell them about cancer risk and outcomes if they are on biologic therapy for RA? br / iMedscape Rheumatology/i
Category:   Articles > Pharmacists


3. Fracture Risk and BMD Reduction Associated With PPIsFracture Risk and BMD Reduction Associated With
  This review summarizes bone risk associated with prolonged PPI therapy. Pharmacotherapy
Category:   Articles > Pharmacists


4. Galantamine Selectively Improves Aspects of Cognition in Schizophrenia
  While galantamine does not provide a significant global benefit for cognitive impairments in schizophrenic patients, it does appear to selectively improve verbal memory and other categories on neuropsychological tests. Reuters Health Information
Category:   Articles > Pharmacists


5. Thalidomide Ineffective for Small Cell Lung Cancer
  For patients with small cell lung cancer, treatment with thalidomide does not improve survival or quality of life, according to a phase III clinical trial published in the Journal of the National Cancer Institute on August 5. The anti-angiogenic agent does, however, increase the risk for peripheral neuropathy and thrombotic events. Reuters Health Information
Category:   Articles > Pharmacists




Home      New Listings      Hot Listings      Top Rated      Editor Pick      Add a Listing      Update a Listing      Get Rated      Upgrade a Listing
Valid XHTML 1.0 Transitional   Valid CSS